Pharmacy Team Innovates 3D-Printed Bandage to Accelerate Healing of Chronic Wounds

A team of researchers at the University of Mississippi is pioneering a transformative approach to chronic wound treatment through the innovative use of 3D printing technology combined with natural, biodegradable materials. Chronic wounds, such as diabetic ulcers and pressure sores, represent a significant clinical challenge due to their prolonged healing times and susceptibility to infection. These wounds are often complicated by poor oxygenation and bacterial colonization, factors that impede the normal tissue repair process. The research team has engineered a customizable wound scaffold that serves as a breathable patch-like structure, designed not only to protect the wound site but also to actively promote healing through sustained delivery of natural antibacterial agents.

At the forefront of this research is Michael Repka, a distinguished professor specializing in pharmaceutics and drug delivery, who alongside colleagues Sateesh Vemula, a postdoctoral researcher, and doctoral candidate Nouf Alshammari are reshaping wound care paradigms. Their strategy hinges on employing 3D printing to fabricate scaffolds from chitosan, a biopolymer extracted from the shells of crustaceans, insects, and fungi. Chitosan’s inherent properties are multifaceted: it accelerates keratinocyte proliferation, modulates inflammatory responses, and curbs microbial invasion, making it an exceptional medium for wound dressings. By incorporating plant-derived antimicrobial compounds within the scaffold, the team has introduced a sustainable alternative to traditional antibiotics that mitigates the risk of bacterial resistance.

The unique aspect of this scaffold lies in its customizable nature, enabled by 3D printing technology. This allows for precision tailoring to fit wounds of varying shapes and sizes across different anatomical locations, a critical advantage over conventional flat bandages. The patch’s breathable architecture facilitates optimal oxygen exchange, addressing hypoxia-related delays in healing that are common in patients with diabetes or limited mobility. Furthermore, the absence of organic solvents in the manufacturing process preserves the biocompatibility of the scaffold, reducing potential cytotoxic effects often associated with current bandaging materials.

Chronic wounds are particularly susceptible to becoming infected due to their extended exposure to environmental pathogens and impaired local immune responses. The integration of plant-based antimicrobials within the chitosan scaffold offers targeted microbial suppression without invoking the drawbacks associated with prolonged antibiotic use, such as microbiome disruption and resistance development. This natural antibacterial delivery not only maintains a sterile wound environment but also supports the endogenous healing cascade by limiting secondary complications.

Another significant advantage highlighted by the researchers is the scaffold’s biodegradability. Over time, the material is gradually absorbed into the skin, eliminating the necessity for scaffold removal that commonly requires additional invasive procedures. This property is especially beneficial for wounds situated internally or in locations where dressing changes are challenging or risky. The use of biodegradable scaffolds thus presents a seamless integration into the regenerative process, minimizing patient discomfort and associated healthcare burdens.

The scalability and adaptability of this technology also open up numerous clinical applications beyond chronic dermal wounds. Repka and his team envision deployment scenarios such as battlefield environments where rapid fabrication of wound dressings could be lifesaving. With portable generators powering 3D printers, customized scaffolds could be produced on-demand to address traumatic injuries with precision and expediency, a capability that could revolutionize emergency and military medicine.

Despite the promising advances, the road to clinical adoption requires rigorous evaluation and regulatory approval. The researchers acknowledge that their prototypes must undergo further preclinical testing to assess safety, efficacy, and long-term outcomes before they can be integrated into standard medical protocols. This translational effort will involve collaboration with the Food and Drug Administration to meet stringent guidelines for medical devices, ensuring patient safety and consistent performance.

In summary, the University of Mississippi research group has developed a cutting-edge, 3D-printed wound scaffold employing chitosan and natural antibacterial agents that offers a biocompatible, customizable, and infection-resistant solution for chronic wound management. This technology not only addresses longstanding challenges in the treatment of persistent wounds but also introduces a new paradigm in personalized wound care. By leveraging the advantages of additive manufacturing and biodegradable materials, the scaffold represents a significant leap forward in regenerative medicine and pharmaceutics.

Furthermore, the intrinsic properties of chitosan combined with plant-derived compounds provide a synergistic effect essential for promoting skin regeneration while preventing infection, all without the adverse impacts of traditional chemical bandages or systemic antibiotics. This research underscores the potential for biologically inspired, engineered materials to accelerate healing processes and improve outcomes for patients burdened by chronic wounds worldwide.

The team’s future objectives include refining scaffold formulations, expanding the range of antimicrobial agents, and optimizing printing techniques to enhance mechanical strength and patient comfort. Their pioneering work sets a precedent for integrating natural substances in drug delivery systems via advanced fabrication technologies, potentially inspiring similar innovations in other areas of healthcare. Ultimately, this 3D-printed, medicated patch could become a cornerstone treatment for complex wounds, fostering faster recovery, reducing healthcare costs, and enhancing quality of life for millions globally.

News Publication Date: Not specified

Web References:
https://pharmacy.olemiss.edu/
https://olemiss.edu/pharmaceutics/
https://www.sciencedirect.com/science/article/pii/S0939641125003315?via%3Dihub
https://pmc.ncbi.nlm.nih.gov/articles/PMC10983058/

References:
Repka M, Vemula S, Alshammari N. European Journal of Pharmaceutics and Biopharmaceutics